Pharmaceutical and biotechnology companies currently spend millions of pounds each working day on global research and development of new therapeutics for a range of diseases. Many of these firms have highly demanding research targets and aim to deliver as many as 15 candidate drugs annually. Nowhere is this felt more keenly than by those involved in genomics and proteomics research for drug discovery. Since these are relatively new fields, they still have to prove that they can help to generate good clinical candidates. Therefore, these groups are constantly trying to find ways of improving the speed and precision of their pre-clinical research processes in order to deliver promising results rapidly. This is where automation can help to improve accuracy and reduce substantial bottlenecks in areas such as quantification of nucleic acids and proteins, as well as counting recombinant clones.

This content is only available as a PDF.